88443079 - THERADIGM

Information

• Trademark
• 88443079

• Source

• Serial Number

  88443079

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  May 23, 2019
  5 years ago

• Transaction Date

  January 30, 2024
  a year ago

• Status Date

  January 02, 2023
  2 years ago

• Published for Opposition Date

  October 01, 2019
  5 years ago

• Location Date

  May 23, 2022
  2 years ago

• Status Code

  606

• Current Location

  INTENT TO USE SECTION

  Employee Name

  NEHMER, JASON ROBERT

• Attorney Docket Number

  399247-1

  Attorney Name

  Keith W. Medansky

  Law Office Assigned Location Code

  N30

• Owners

  • VESTA THERAPEUTICS, INC

Case File Statements

• GS0401: Biomanufacturing for others, namely, manufacturing of biologics, cells, scaffolds and matrices, and related biological materials using biological organisms in the manufacturing process
• GS0051: Biologics, namely, cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely, stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism
• GS0011: Biologics, namely, cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely, cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely, cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances
• GS0441: Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism
• GS0421: Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells

Case File Event Statements

• 1/3/2023 - 2 years ago

  37 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Type: MAB6

• 1/2/2023 - 2 years ago

  36 - ABANDONMENT - NO USE STATEMENT FILED Type: ABN6

• 5/24/2022 - 2 years ago

  35 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 5/23/2022 - 2 years ago

  34 - SOU EXTENSION 5 GRANTED Type: EX5G

• 5/18/2022 - 2 years ago

  33 - SOU EXTENSION 5 FILED Type: EXT5

• 5/23/2022 - 2 years ago

  32 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 5/18/2022 - 2 years ago

  31 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 1/28/2022 - 3 years ago

  30 - ASSIGNED TO EXAMINER Type: DOCK

• 10/28/2021 - 3 years ago

  29 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 10/26/2021 - 3 years ago

  28 - SOU EXTENSION 4 GRANTED Type: EX4G

• 10/26/2021 - 3 years ago

  27 - SOU EXTENSION 4 FILED Type: EXT4

• 10/26/2021 - 3 years ago

  26 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 4/29/2021 - 3 years ago

  25 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 4/27/2021 - 3 years ago

  24 - SOU EXTENSION 3 GRANTED Type: EX3G

• 4/27/2021 - 3 years ago

  23 - SOU EXTENSION 3 FILED Type: EXT3

• 4/27/2021 - 3 years ago

  22 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 11/18/2020 - 4 years ago

  21 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 11/16/2020 - 4 years ago

  20 - SOU EXTENSION 2 GRANTED Type: EX2G

• 11/16/2020 - 4 years ago

  19 - SOU EXTENSION 2 FILED Type: EXT2

• 11/16/2020 - 4 years ago

  18 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 5/9/2020 - 4 years ago

  17 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 5/7/2020 - 4 years ago

  16 - SOU EXTENSION 1 GRANTED Type: EX1G

• 5/7/2020 - 4 years ago

  15 - SOU EXTENSION 1 FILED Type: EXT1

• 5/7/2020 - 4 years ago

  14 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 11/26/2019 - 5 years ago

  13 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 10/1/2019 - 5 years ago

  12 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 10/1/2019 - 5 years ago

  11 - PUBLISHED FOR OPPOSITION Type: PUBO

• 9/11/2019 - 5 years ago

  10 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 8/29/2019 - 5 years ago

  9 - ASSIGNED TO LIE Type: ALIE

• 8/21/2019 - 5 years ago

  8 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 8/19/2019 - 5 years ago

  7 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 8/19/2019 - 5 years ago

  6 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 8/19/2019 - 5 years ago

  5 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 8/19/2019 - 5 years ago

  4 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 8/13/2019 - 5 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 6/7/2019 - 5 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 5/27/2019 - 5 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP